Read by QxMD icon Read

antoni ribas

Alex A Adjei, Patricia LoRusso, Antoni Ribas, Jeffrey A Sosman, Anna Pavlick, Grace K Dy, Xiaofei Zhou, Esha Gangolli, Michelle Kneissl, Stephanie Faucette, Rachel Neuwirth, Viviana Bózon
Purpose TAK-733, an investigational, selective, allosteric MEK1/2 inhibitor, has demonstrated antitumor effects against multiple cancer cell lines and xenograft models. This first-in-human study investigated TAK-733 in patients with solid tumors. Methods Patients received oral TAK-733 once daily on days 1-21 in 28-day treatment cycles. Adverse events (AEs) were graded using the Common Terminology Criteria for AEs version 3.0. Response was assessed using RECIST v1.1. Blood samples for TAK-733 pharmacokinetics and pharmacodynamics (inhibition of ERK phosphorylation) were collected during cycle 1...
September 21, 2016: Investigational New Drugs
Bjoern Titz, Anastasia Lomova, Allison Le, Willy Hugo, Xiangju Kong, Johanna Ten Hoeve, Michael Friedman, Hubing Shi, Gatien Moriceau, Chunying Song, Aayoung Hong, Mohammad Atefi, Richard Li, Evangelia Komisopoulou, Antoni Ribas, Roger S Lo, Thomas G Graeber
A prominent mechanism of acquired resistance to BRAF inhibitors in BRAF (V600) -mutant melanoma is associated with the upregulation of receptor tyrosine kinases. Evidences suggested that this resistance mechanism is part of a more complex cellular adaptation process. Using an integrative strategy, we found this mechanism to invoke extensive transcriptomic, (phospho-) proteomic and phenotypic alterations that accompany a cellular transition to a de-differentiated, mesenchymal and invasive state. Even short-term BRAF-inhibitor exposure leads to an early adaptive, differentiation state change-characterized by a slow-cycling, persistent state...
2016: Cell Discovery
Blanca Homet Moreno, Stephen Mok, Begonya Comin-Anduix, Siwen Hu-Lieskovan, Antoni Ribas
The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF (V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreated metastatic melanoma and the synergistic effect of dabrafenib, trametinib and anti-PD-1 compared with single therapy alone groups support the idea that combining dabrafenib, trametinib and immunotherapy based on PD-1 blockade could be an interesting approach in the treatment of metastatic melanoma...
July 2016: Oncoimmunology
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, Caroline Robert, Omid Hamid, Adil Daud, Alfons van den Eertwegh, Lee Cranmer, Steven O'Day, Igor Puzanov, Jacob Schachter, Christian Blank, April Salama, Carmen Loquai, Janice M Mehnert, Darcy Hille, Scot Ebbinghaus, S Peter Kang, Wei Zhou, Antoni Ribas
BACKGROUND: In KEYNOTE-002, pembrolizumab significantly prolonged progression-free survival and was associated with a better safety profile compared with chemotherapy in patients with advanced melanoma that progressed after ipilimumab. We present health-related quality of life (HRQoL) outcomes from KEYNOTE-002. METHODS: Patients were randomly assigned 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks (Q3W) or investigator-choice chemotherapy. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 instrument...
November 2016: European Journal of Cancer
Blanca Homet Moreno, Jesse M Zaretsky, Angel Garcia-Diaz, Jennifer Tsoi, Giulia Parisi, Lidia Robert, Katrina Meeth, Abibatou Ndoye, Marcus Bosenberg, Ashani T Weeraratna, Thomas G Graeber, Begoña Comin-Anduix, Siwen Hu-Lieskovan, Antoni Ribas
The programmed cell death protein 1 (PD-1) limits effector T-cell functions in peripheral tissues, and its inhibition leads to clinical benefit in different cancers. To better understand how PD-1 blockade therapy modulates the tumor-host interactions, we evaluated three syngeneic murine tumor models, the BRAF(V600E)-driven YUMM1.1 and YUMM2.1 melanomas, and the carcinogen-induced murine colon adenocarcinoma MC38. The YUMM cell lines were established from mice with melanocyte-specific BRAF(V600E) mutation and PTEN loss (BRAF(V600E)/PTEN(-/-))...
October 2016: Cancer Immunology Research
James S Economou, Dennis J Slamon, Antoni Ribas, Michael E Phelps
No abstract text is available yet for this article.
October 2016: Annals of Surgery
Alexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, Patrick A Ott, Douglas B Johnson, Katy K Tsai, Suthee Rapisuwon, Zeynep Eroglu, Ryan J Sullivan, Jason J Luke, Tara C Gangadhar, April K S Salama, Varina Clark, Clare Burias, Igor Puzanov, Michael B Atkins, Alain P Algazi, Antoni Ribas, Jedd D Wolchok, Michael A Postow
BACKGROUND: Therapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described. METHODS: A multi-institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through expanded access programs or published prospective trials...
August 17, 2016: Cancer
Helena Escuin-Ordinas, Shuoran Li, Michael W Xie, Lu Sun, Willy Hugo, Rong Rong Huang, Jing Jiao, Felipe Meira de-Faria, Susan Realegeno, Paige Krystofinski, Ariel Azhdam, Sara Marie D Komenan, Mohammad Atefi, Begoña Comin-Anduix, Matteo Pellegrini, Alistair J Cochran, Robert L Modlin, Harvey R Herschman, Roger S Lo, William H McBride, Tatiana Segura, Antoni Ribas
BRAF inhibitors are highly effective therapies for the treatment of BRAF(V600)-mutated melanoma, with the main toxicity being a variety of hyperproliferative skin conditions due to paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in BRAF wild-type cells. Most of these hyperproliferative skin changes improve when a MEK inhibitor is co-administered, as it blocks paradoxical MAPK activation. Here we show how the BRAF inhibitor vemurafenib accelerates skin wound healing by inducing the proliferation and migration of human keratinocytes through extracellular signal-regulated kinase (ERK) phosphorylation and cell cycle progression...
2016: Nature Communications
Jesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Davis Y Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly, Justin Saco, Blanca Homet Moreno, Riccardo Mezzadra, Bartosz Chmielowski, Kathleen Ruchalski, I Peter Shintaku, Phillip J Sanchez, Cristina Puig-Saus, Grace Cherry, Elizabeth Seja, Xiangju Kong, Jia Pang, Beata Berent-Maoz, Begoña Comin-Anduix, Thomas G Graeber, Paul C Tumeh, Ton N M Schumacher, Roger S Lo, Antoni Ribas
BACKGROUND: Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this context are unknown. METHODS: We analyzed biopsy samples from paired baseline and relapsing lesions in four patients with metastatic melanoma who had had an initial objective tumor regression in response to anti-PD-1 therapy (pembrolizumab) followed by disease progression months to years later...
September 1, 2016: New England Journal of Medicine
Miguel Caballero-Baños, Daniel Benitez-Ribas, Jaime Tabera, Sara Varea, Ramon Vilana, Luis Bianchi, Juan Ramón Ayuso, Mario Pagés, Gemma Carrera, Miriam Cuatrecasas, Marta Martin-Richard, Joan Cid, Miguel Lozano, Antoni Castells, Xabier García-Albéniz, Joan Maurel, Ramon Vilella
BACKGROUND: Autologous tumour lysate dendritic cell vaccine (ADC) has T-cell stimulatory capacity and, therefore, potential antitumour activity. We designed a phase II randomised trial of ADC + best supportive care (BSC) (experimental arm [EA]) compared with BSC (control arm [CA]), in pre-treated metastatic colorectal cancer (mCRC) patients. PATIENTS AND METHODS: Patients with progressive mCRC, at least to two chemotherapy regimens and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2, were randomised to EA versus CA...
September 2016: European Journal of Cancer
Amanpreet Kaur, Marie R Webster, Katie Marchbank, Reeti Behera, Abibatou Ndoye, Curtis H Kugel, Vanessa M Dang, Jessica Appleton, Michael P O'Connell, Phil Cheng, Alexander A Valiga, Rachel Morissette, Nazli B McDonnell, Luigi Ferrucci, Andrew V Kossenkov, Katrina Meeth, Hsin-Yao Tang, Xiangfan Yin, William H Wood, Elin Lehrmann, Kevin G Becker, Keith T Flaherty, Dennie T Frederick, Jennifer A Wargo, Zachary A Cooper, Michael T Tetzlaff, Courtney Hudgens, Katherine M Aird, Rugang Zhang, Xiaowei Xu, Qin Liu, Edmund Bartlett, Giorgos Karakousis, Zeynep Eroglu, Roger S Lo, Matthew Chan, Alexander M Menzies, Georgina V Long, Douglas B Johnson, Jeffrey Sosman, Bastian Schilling, Dirk Schadendorf, David W Speicher, Marcus Bosenberg, Antoni Ribas, Ashani T Weeraratna
No abstract text is available yet for this article.
July 6, 2016: Nature
Mohammad Atefi, Bjoern Titz, Jennifer Tsoi, Earl Avramis, Allison Le, Charles Ng, Anastasia Lomova, Amanda Lassen, Michael Friedman, Bartosz Chmielowski, Antoni Ribas, Thomas G Graeber
Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known. We established a melanoma cell line from a tumor with none of the common driver mutations. This cell line demonstrated a signaling profile similar to BRAF-mutants, but lacked sensitivity to the BRAF inhibitor vemurafenib. RNA-seq mutation data implicated CRAF R391W as the alternative driver mutation of this melanoma...
2016: Scientific Reports
Elena Delgado-Mejía, Guillem Frontera-Juan, Javier Murillas-Angoiti, Antoni Abdon Campins-Roselló, Leire Gil-Alonso, María Peñaranda-Vera, María Angels Ribas Del Blanco, María Luisa Martín-Pena, Melchor Riera-Jaume
INTRODUCTION: In 2010, the AIDS Study Group (Grupo de Estudio del SIDA [GESIDA]) developed 66 quality care indicators. The aim of this study is to determine which of these indicators are associated with mortality and hospital admission, and to perform a preliminary assessment of a prediction rule for mortality and hospital admission in patients on treatment and follow-up. METHODS: A retrospective cohort study was conducted in the Hospital Universitario Son Espases (Palma de Mallorca, Spain)...
June 4, 2016: Enfermedades Infecciosas y Microbiología Clínica
Christian U Blank, John B Haanen, Antoni Ribas, Ton N Schumacher
No abstract text is available yet for this article.
May 6, 2016: Science
Antoni Ribas, Omid Hamid, Adil Daud, F Stephen Hodi, Jedd D Wolchok, Richard Kefford, Anthony M Joshua, Amita Patnaik, Wen-Jen Hwu, Jeffrey S Weber, Tara C Gangadhar, Peter Hersey, Roxana Dronca, Richard W Joseph, Hassane Zarour, Bartosz Chmielowski, Donald P Lawrence, Alain Algazi, Naiyer A Rizvi, Brianna Hoffner, Christine Mateus, Kevin Gergich, Jill A Lindia, Maxine Giannotti, Xiaoyun Nicole Li, Scot Ebbinghaus, S Peter Kang, Caroline Robert
IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months...
April 19, 2016: JAMA: the Journal of the American Medical Association
Glenn Merlino, Meenhard Herlyn, David E Fisher, Boris C Bastian, Keith T Flaherty, Michael A Davies, Jennifer A Wargo, Clara Curiel-Lewandrowski, Michael J Weber, Sancy A Leachman, Maria S Soengas, Martin McMahon, J William Harbour, Susan M Swetter, Andrew E Aplin, Michael B Atkins, Marcus W Bosenberg, Reinhard Dummer, Jeffrey E Gershenwald, Allan C Halpern, Dorothee Herlyn, Giorgos C Karakousis, John M Kirkwood, Michael Krauthammer, Roger S Lo, Georgina V Long, Grant McArthur, Antoni Ribas, Lynn Schuchter, Jeffrey A Sosman, Keiran S Smalley, Patricia Steeg, Nancy E Thomas, Hensin Tsao, Thomas Tueting, Ashani Weeraratna, George Xu, Randy Lomax, Alison Martin, Steve Silverstein, Tim Turnham, Ze'ev A Ronai
The Melanoma Research Foundation (MRF) has charted a comprehensive assessment of the current state of melanoma research and care. Intensive discussions among members of the MRF Scientific Advisory Council and Breakthrough Consortium, a group that included clinicians and scientists, focused on four thematic areas - diagnosis/early detection, prevention, tumor cell dormancy (including metastasis), and therapy (response and resistance). These discussions extended over the course of 2015 and culminated at the Society of Melanoma Research 2015 International Congress in November...
July 2016: Pigment Cell & Melanoma Research
Amanpreet Kaur, Marie R Webster, Katie Marchbank, Reeti Behera, Abibatou Ndoye, Curtis H Kugel, Vanessa M Dang, Jessica Appleton, Michael P O'Connell, Phil Cheng, Alexander A Valiga, Rachel Morissette, Nazli B McDonnell, Luigi Ferrucci, Andrew V Kossenkov, Katrina Meeth, Hsin-Yao Tang, Xiangfan Yin, William H Wood, Elin Lehrmann, Kevin G Becker, Keith T Flaherty, Dennie T Frederick, Jennifer A Wargo, Zachary A Cooper, Michael T Tetzlaff, Courtney Hudgens, Katherine M Aird, Rugang Zhang, Xiaowei Xu, Qin Liu, Edmund Bartlett, Giorgos Karakousis, Zeynep Eroglu, Roger S Lo, Matthew Chan, Alexander M Menzies, Georgina V Long, Douglas B Johnson, Jeffrey Sosman, Bastian Schilling, Dirk Schadendorf, David W Speicher, Marcus Bosenberg, Antoni Ribas, Ashani T Weeraratna
Cancer is a disease of ageing. Clinically, aged cancer patients tend to have a poorer prognosis than young. This may be due to accumulated cellular damage, decreases in adaptive immunity, and chronic inflammation. However, the effects of the aged microenvironment on tumour progression have been largely unexplored. Since dermal fibroblasts can have profound impacts on melanoma progression, we examined whether age-related changes in dermal fibroblasts could drive melanoma metastasis and response to targeted therapy...
April 14, 2016: Nature
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Shirley Lomeli, Xiangju Kong, Mark C Kelley, Jeffrey A Sosman, Douglas B Johnson, Antoni Ribas, Roger S Lo
PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identify factors that may influence innate sensitivity or resistance to anti-PD-1 therapy. We find that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2. Innately resistant tumors display a transcriptional signature (referred to as the IPRES, or innate anti-PD-1 resistance), indicating concurrent up-expression of genes involved in the regulation of mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing...
March 24, 2016: Cell
Holbrook E Kohrt, Paul C Tumeh, Don Benson, Nina Bhardwaj, Joshua Brody, Silvia Formenti, Bernard A Fox, Jerome Galon, Carl H June, Michael Kalos, Ilan Kirsch, Thomas Kleen, Guido Kroemer, Lewis Lanier, Ron Levy, H Kim Lyerly, Holden Maecker, Aurelien Marabelle, Jos Melenhorst, Jeffrey Miller, Ignacio Melero, Kunle Odunsi, Karolina Palucka, George Peoples, Antoni Ribas, Harlan Robins, William Robinson, Tito Serafini, Paul Sondel, Eric Vivier, Jeff Weber, Jedd Wolchok, Laurence Zitvogel, Mary L Disis, Martin A Cheever
The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically targeted agents raise new challenges to conventional drug development paradigms by highlighting the limited relevance of assessing standard pharmacokinetics (PK) and pharmacodynamics (PD). Specifically, systemic and intratumoral immune effects have not consistently correlated with standard relationships between systemic dose, toxicity, and efficacy for cytotoxic therapies...
2016: Journal for Immunotherapy of Cancer
F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jeffrey S Weber, Adil Daud, Omid Hamid, Amita Patnaik, Antoni Ribas, Caroline Robert, Tara C Gangadhar, Anthony M Joshua, Peter Hersey, Roxana Dronca, Richard Joseph, Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S Peter Kang, Scot Ebbinghaus, Andrea Perrone, Jedd D Wolchok
PURPOSE: We evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in patients with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). PATIENTS AND METHODS: Patients received pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks...
May 1, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"